No products in the cart
Cardiogen peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the Cardiogen Peptide?
Cardiogen is a cardiovascular bioregulator peptide complex. It is a dietary additive with a synthesized heart peptide. It was developed to alternate heart functions to address peptide deficiency and restore the synthesis of protein in the heart cells. Results obtained from research studies suggest that Cardiogen’s primary functions are exhibited in fibroblasts, cells responsible for scar formation, and tissue repair throughout the body. This peptide focuses on the cardiovascular system, hence the name. Through the synergistic peptide, it appears to enhance the effects and advantages of some standard therapies, which could amount to long-term outcomes even as it reduces side effects.
The research on rat models suggest also that Cardiogen may multiply apoptosis rates in tumor cells.
Molecular Formula: C18H31N7O9
Molecular Weight: 489.5 g/mol
Peptide complex AKS-K (peptide-linked amino acids): Glutamic, aspartic, alanine, arginine. Inactive ingredients: Microcrystalline cellulose (E460), beetroot sugar, lactose, starch, Tween-80, 60 capsules.
PubChem: CID 11583989
Cardiogen and the Heart
Cardiogen appears to stimulate the proliferation of cardiomyocytes, reducing the growth and development of fibroblasts and causing a reduction in the formation of scars, allowing for improved long-term outcomes in cardiac remodeling that may result in congestive cardiac failure. Moreover, researchers suggest that Cardiogen may cause a decrease in the expression of the p53 protein, which may result in a reduced rate of apoptosis. In older adults, Cardiogen has been studied as a possible therapy for hypertension, heart failure, attacks of angina pectoris, coronary heart disease, myocardial hypertrophy, myocarditis, and myocardiodystrophy. It has also been researched for its potential to increase stamina under heavy loads and adverse environmental factors (as in the case of athletes, submarines, and others). The treatment and prevention of cardiovascular diseases via Cardiogen may allow patients to attain active longevity and decrease the risk of pathologies in the heart muscle.
Cardiogen and the Prostate
Cardiogen, along with several similarly structured peptides, may cause positive changes in the expression of signaling factors in the fibroblasts of proteins. Signaling factors are responsible for fostering the development and succession of prostate cancer. In aging and senescent fibroblasts, these signaling factors are altered. This alteration explains why prostate cancer is ever-present in older men but is rarely evident in younger men. These studies suggest that Cardiogen may play a vital role in bringing these signaling factors to normal levels, to be identical or even better than what is in young cell cultures. These studies show promise for detailed development of methods of peptides’ regulation of aging and age-correction of violations of functioning of the prostate gland. Cardiogen may be an essential substance in both the prevention of prostate cancer and managing the succession of prostate cancer development.
Cardiogen and Cancer Cells
Research suggests that Cardiogen may be an effective reductant of apoptosis in the cardiomyocytes via decreasing the expression of p53, and that it may also have an opposite effect in tumor cells. The tumor-modifying effect of Cardiogen, which was experimented on rat models with M-1 sarcoma, reported that apoptosis on tumor cells appeared to be higher than usual and beyond control. The study also suggested that this was due to the development of necrotic hemorrhagic and the enhancement of tumor cell apoptosis. This proliferative activity may indicate that tumor growth inhibition is not due to the direct effect of a cytostatic medicine on the tumor. Morphology has suggested that it may be due to a particular mechanism of action of the peptide. This process may be the case for some tumor cells because of their increased and atypical vascular supply. Due to this, the use of Cardiogen may be effective in treating some types of cancer. If it increases the action of standard cancer treatments, the peptide might be used as a potent additive to the armaments for fighting cancer. In Russia, the Cardiogen peptide may soon be considered a potential option in treating sarcoma. This result is a consequence of the research extensively carried out by Doctors Levdik and Knyazkin, who worked with Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. This research is affiliated with the Russian Academy of Medical Sciences.
Cardiogen is intended as a research chemical only, and is the least experiemented compared to the other bioregulators, but indicates its potency on multiple body issues including the heart and prostate. Cardiogen may prove to be beneficial in treating certain types of cancers – sarcoma in contrast. The benefits of this peptide may be effective in heart attack, chronic heart failure, and hypertension, but in a symbiotic manner with established treatments. Experimental research reports that Cardiogen doesn’t appear to have identifiable side effects, and doesn’t seem to cause addiction or allergic reactions. Although, contraindications might be evident in intolerable individuals, pregnancy, and lactation. Rat and mice models exhibit minimal side effects and good oral and excellent subcutaneous bioavailability.
- Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K.h, & Vanyushin, B. F. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry. Biokhimiia, 76(11), 1210–1219. https://doi.org/10.1134/S0006297911110022
- Chalisova NI, Lesniak VV, Balykina NA, et al. [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]. Advances in Gerontology = Uspekhi Gerontologii. 2009 ;22(3):409-413. PMID: 20210190.
- Kheĭfets OV, Poliakova VO, Kvetnoĭ IM. [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]. Advances in Gerontology = Uspekhi Gerontologii. 2010 ;23(1):68-70. PMID: 20586252.
- Zakutskiĭ, A. N., Chalisova, N. I., & Subbotina, T. F. (2008). Bioorganicheskaia khimiia, 34(2), 149–159. https://doi.org/10.1134/s1068162008020015
- Levdik, N. V., & Knyazkin, I. V. (2009). Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of experimental biology and medicine, 148(3), 433–436. https://doi.org/10.1007/s10517-010-0730-9
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.
There are no reviews yet.